BofA Notes Positive Interest in Novavax, Inc. (NVAX) Technology Despite Timing Concerns for Licensed Assets

We recently compiled a list of the 9 High Growth Small Cap Stocks That Are Profitable. Novavax, Inc. stands second on our list of high growth stocks. TheFly reported on January 20 that BofA raised its price target on NVAX to $7 from $6 while maintaining an Underperform rating. The update followed the company’s announcement of a non-exclusive licensing deal with Pfizer for its Matrix-M adjuvant across up to two infectious disease areas. While BofA views the agreement and upfront payment as positive signs o ...